DAX23.630 -1,5%ESt505.326 -1,8%Top 10 Crypto14,25 -2,1%Dow41.617 -0,6%Nas18.743 -1,0%Bitcoin95.787 -3,2%Euro1,1360 +0,7%Öl64,92 +1,4%Gold3.361 +1,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 RENK RENK73 D-Wave Quantum A3DSV9 Siemens Energy ENER6Y Deutsche Bank 514000 Bayer BAY001 Tesla A1CX3T BYD A0M4W9 Lufthansa 823212 HENSOLDT HAG000 Infineon 623100 Deutsche Telekom 555750 Apple 865985 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Rote Vorzeichen an den US-Börsen -- DAX geht weit unter 24.000er-Marke ins Wochenende -- Quantencomputing-Aktien IonQ und D-Wave treiben Rally an -- Meta, Apple, Reddit, Amazon, Rheinmetall im Fokus
Top News
Boeing bekommt neuen Deal mit US-Regierung zu Max-Abstürzen Boeing bekommt neuen Deal mit US-Regierung zu Max-Abstürzen
Trump: Neue iPhone-Zölle sollen auch für andere Hersteller gelten Trump: Neue iPhone-Zölle sollen auch für andere Hersteller gelten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Montag um 18 Uhr live: 600% Momentum-Strategie - Die perfekte Trading-Taktik für 2025 - Jetzt kostenlos anmelden!

Nektar Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,5540 EUR -0,0140 EUR -2,46 %
STU
0,6481 USD +0,0040 USD +0,62 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.108,35 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN165417

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6402681083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNKTR

Nektar Therapeutics Aktien News

DatumMeistgelesen
PR NewswireNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
PR NewswireNektar Therapeutics Reports First Quarter 2025 Financial Results
PR NewswireNektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
Wer­bungNektar Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
PR NewswireNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswireNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
PR NewswireNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
PR NewswireNektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
PR NewswireNektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
PR NewswireNektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
PR NewswireNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
PR NewswireNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH M...
PR NewswireNektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
PR NewswireNektar Therapeutics Reports Third Quarter 2024 Financial Results
PR NewswireNektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at ...
PR NewswireNektar Therapeutics to Participate in Upcoming Investor Conferences
PR NewswireNektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
PR NewswireNektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
PR NewswireNektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
PR NewswireNektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
PR NewswireNektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
PR NewswireNektar Management to Present at Upcoming Investor Conferences
PR NewswireNektar Therapeutics Reports Second Quarter 2024 Financial Results
PR NewswireNektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
PR NewswireNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
PR NewswireNektar Management to Present at Upcoming Investor Conferences
PR NewswireNektar Therapeutics Reports First Quarter 2024 Financial Results
PR NewswireNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
PR NewswireNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PR NewswireNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
PR NewswireNektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
PR NewswireNektar Management to Present at the TD Cowen 44th Annual Health Care Conference
PR NewswireNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
PR NewswireNektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
PR NewswireNektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
PR NewswireNektar Therapeutics Reports Third Quarter 2023 Financial Results
PR NewswireNektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
PR NewswireNektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
PR NewswireNektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
PR NewswireNektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
Wer­bung

Nektar Therapeutics News

Nektar Therapeutics News: auf dieser Seite finden Sie alle Nektar Therapeutics News und Nachrichten zur Nektar Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Nektar Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Nektar Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.